On Monday medical device maker Covidien reported that it had completed the sale of its sleep diagnostics assets – including several products sold under the Sandman brand – to Embla Systems. The agreement was previously announced on Sept. 3. According to a company news release, Covidien is streamlining its portfolio and reallocating resources to its "faster-growing, higher-margin businesses."
On Sept. 3 Covidien also announced that it has proposed the sale of its sleep therapy product line; this includes several products sold under the Sandman, DreamFit, GoodKnight and Breeze brands.
